IX BIOPHARMA LTD.
(Company Registration Number 200405621W)
(Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT TO RAISE GROSS PROCEEDS OF NO LESS THAN S$6,000,000 – RECEIPT OF LISTING AND QUOTATION NOTICE

The Board of Directors of iX Biopharma Ltd. (the "**Company**") (the "**Board**" or the "**Directors**") refers to its announcements dated 12 February 2026 and 13 February 2026, in relation to (a) the entry into a placement agreement with Oversea-Chinese Banking Corporation Limited and (b) the results of the Proposed Placement, respectively (collectively, the "**Announcements**").

Unless otherwise defined, all capitalised terms used herein shall have the same meaning as ascribed to them in the Announcements.

Further to the Announcements, the Board is pleased to announce that the Company has on 19 February 2026, received the listing and quotation notice pursuant to which the Singapore Exchange Securities Trading Limited ("**SGX-ST**") has approved in-principle the listing and quotation of up to 75,800,000 New Shares pursuant to the Proposed Placement, subject to compliance with the listing requirements of the SGX-ST. The SGX-ST's in-principle approval is not to be taken as an indication of the merits of the Proposed Placement, the Company, its subsidiaries or its Shares.

The Company will continue to keep its shareholders updated and release announcements relating to the Proposed Placement (including any material developments and progress made) as may be appropriate from time to time.

Shareholders and potential investors should note that the Proposed Placement is subject to the fulfilment of, *inter alia*, the conditions set out under the Placement Agreement, and should exercise caution when trading in the Shares of the Company. Persons who are in doubt as to the action they should take should consult their legal, financial, tax or other professional advisers.

By Order of the Board
IX BIOPHARMA LTD.

Eddy Lee Yip Hang
Chairman & CEO

19 February 2026

---

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.

IMPORTANT NOTICE

NOT FOR DISTRIBUTION IN THE UNITED STATES

THIS ANNOUNCEMENT IS NOT AN OFFER FOR SALE OF SECURITIES IN THE UNITED STATES. THE NEW SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, (THE "**SECURITIES ACT**") OR THE SECURITIES LAWS OF ANY STATE OF THE U.S. OR OTHER JURISDICTION, AND THE NEW SHARES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.